As little is known about the antitumor efficacy and resistance of nimotuzumab in combination with TMZ in those GBM‐overexpressing EGFRvIII or wtEGFR, our purpose will be to investigate in vivo the growth‐inhibitory effects of nimotuzumab alone and in combination with TMZ in GBM cell lines that overexpress EGFR species and the changes in molecular determinants studying the mechanisms for sensitivity of tumor cells that had evaded the nimotuzumab/TMZ combination treatment. Here, EGFR is linked to neoplasm.